Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)

Trial Profile

TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs PSMA 617 (Primary) ; Cabazitaxel
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TheraP
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Jun 2018 According to an Endocyte media release, an image of PET scans of eight patients before treatment with 177Lu-PSMA-617 and at three months following treatment from this trial was selected at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting as the Image of the Year.
    • 16 May 2018 According to Endocyte media release, data from this trial will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top